核酸
核糖核酸
RNA干扰
癌症研究
胶质瘤
寡核苷酸
生物
脑瘤
小RNA
RNA沉默
基因敲除
DNA
医学
病理
细胞凋亡
基因
生物化学
作者
Monika Piwecka,Katarzyna Rolle,Eliza Wyszko,R Zukiel,S. Nowak,Mirosława Z. Barciszewska,Jan Barciszewski
出处
期刊:Current Pharmaceutical Biotechnology
[Bentham Science]
日期:2011-11-01
卷期号:12 (11): 1805-1822
被引量:13
标识
DOI:10.2174/138920111798377067
摘要
Malignant gliomas are the deadliest brain tumors, which are characterized by highly invasive growth, a rampant genetic instability and intense resistance to apoptosis. Such an aggressive behavior of malignant gliomas is reflected in the resistance to chemo- and radiotherapy and weak prognosis in spite of cytoreduction through surgery. Brain tumors preferentially express a number of specific protein and RNA markers, that may be exploited as potential therapeutic targets in design of the new treatment modalities based on nucleic acids. For almost three decades, a possibility to apply DNA and RNA molecules as anticancer therapeutics have been studied. A variety of antisense oligonucleotides, ribozymes, DNAzymes, and aptamers can be designed to trigger the sequence-specific inhibition of particular mRNA of interest. RNA interference (RNAi) is the latest and the most promising technique in the long line of nucleic acid-based therapeutic technologies. Recently, we designed and implemented the experimental therapy of patients suffering from malignant brain tumors based on application of double-stranded RNA (dsRNA) specific for tenascin-C (TN-C) mRNA. That therapeutic agent, called ATN-RNA, induces RNAi pathway to inhibit the synthesis of TN-C, the extracellular matrix protein which is highly overexpressed in brain tumor tissue. In the chapter specific problems of application of nucleic acid-based technologies in glioma tumors treatment will be discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI